Cargando…

Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach

BACKGROUND: Despite improved patient outcome using tyrosine kinase inhibitors (TKIs), chronic myeloid leukaemia (CML) patients require life-long treatment due to leukaemic stem cell (LSC) persistence. LSCs reside in the bone marrow (BM) niche, which they modify to their advantage. The BM provides on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Busch, Caroline, Mulholland, Theresa, Zagnoni, Michele, Dalby, Matthew, Berry, Catherine, Wheadon, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685629/ https://www.ncbi.nlm.nih.gov/pubmed/38031192 http://dx.doi.org/10.1186/s12964-023-01363-2

Ejemplares similares

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors
por: Li, Shaoguang, et al.
Publicado: (2007)

Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
por: Liu, Jingjing, et al.
Publicado: (2020)

Dual transcripts of BCR-ABL & different polymorphisms in chronic myeloid leukaemia patients
por: Nandagopalan, S. Rajashree, et al.
Publicado: (2016)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association
por: Faizan, Mahwish, et al.
Publicado: (2021)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
por: Amarante-Mendes, Gustavo P., et al.
Publicado: (2022)

Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients
por: Osman, Emad-Aldin I., et al.
Publicado: (2010)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
por: Khateb, Mamduh, et al.
Publicado: (2012)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
por: Warsch, Wolfgang, et al.
Publicado: (2012)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
por: Samanta, A, et al.
Publicado: (2011)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation
por: Qin, R, et al.
Publicado: (2014)

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
por: Rauzan, Muhammad, et al.
Publicado: (2017)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Wagle, M, et al.
Publicado: (2016)

A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia
por: Menzl, Ingeborg, et al.
Publicado: (2019)

The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia
por: Grassi, Susanna, et al.
Publicado: (2019)

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
por: Eiring, Anna M., et al.
Publicado: (2015)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents
por: Liu, W M, et al.
Publicado: (2002)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
por: Schmidt, Nina, et al.
Publicado: (2022)

Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia
por: McCarron, Sarah L., et al.
Publicado: (2013)

The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia
por: Nestal de Moraes, Gabriela, et al.
Publicado: (2012)

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
por: Quentmeier, Hilmar, et al.
Publicado: (2011)

Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia
por: Cheng, Rubin, et al.
Publicado: (2021)

Potential Role of Notch Signalling in CD34(+) Chronic Myeloid Leukaemia Cells: Cross-Talk between Notch and BCR-ABL
por: Aljedai, Abdullah, et al.
Publicado: (2015)

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions
por: May, Philippa C., et al.
Publicado: (2023)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
por: Virgili, Anna, et al.
Publicado: (2010)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
por: Mitchell, Rebecca, et al.
Publicado: (2017)

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
por: Xie, Vicki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l8sblh3vvo9pi8b7iid04iuuuf